Jessica Mann is currently the GmbH Company Head of Cardiovascular Development Consulting. Her impressive 15+ year record in the pharmaceutical industry includes the development and implementation of clinical programs for Diovan (a Novartis compound). She was also part of the management team that led the IPO of Speedel in 2005.
Prior to joining the pharmaceutical industry, Jessica worked as a cardiologist and cardiovascular pathologist at the National Institutes of Health in Bethesda, MD. She then held a lecturer position at St Georges Hospital Medical School in London, where she completed her PhD and wrote a textbook on cardiovascular pathology.